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Abstract
Background: Parkinson’s disease (PD) is a neurodegenerative disorder whose diagnosis is often challenging because
symptoms may overlap with neurodegenerative parkinsonisms. PD is characterized by intraneuronal accumulation of
abnormal α-synuclein in brainstem while neurodegenerative parkinsonisms might be associated with accumulation of
either α-synuclein, as in the case of Multiple System Atrophy (MSA) or tau, as in the case of Corticobasal Degeneration
(CBD) and Progressive Supranuclear Palsy (PSP), in other disease-specific brain regions. Definite diagnosis of all these
diseases can be formulated only neuropathologically by detection and localization of α-synuclein or tau aggregates in
the brain. Compelling evidence suggests that trace-amount of these proteins can appear in peripheral tissues,
including receptor neurons of the olfactory mucosa (OM).
Methods: We have set and standardized the experimental conditions to extend the ultrasensitive Real Time Quaking
Induced Conversion (RT-QuIC) assay for OM analysis. In particular, by using human recombinant α-synuclein as
substrate of reaction, we have assessed the ability of OM collected from patients with clinical diagnoses of PD and
MSA to induce α-synuclein aggregation, and compared their seeding ability to that of OM samples collected from
patients with clinical diagnoses of CBD and PSP.
Results: Our results showed that a significant percentage of MSA and PD samples induced α-synuclein aggregation
with high efficiency, but also few samples of patients with the clinical diagnosis of CBD and PSP caused the same
effect. Notably, the final RT-QuIC aggregates obtained from MSA and PD samples owned peculiar biochemical and
morphological features potentially enabling their discrimination.
Conclusions: Our study provide the proof-of-concept that olfactory mucosa samples collected from patients with PD
and MSA possess important seeding activities for α-synuclein. Additional studies are required for (i) estimating
sensitivity and specificity of the technique and for (ii) evaluating its application for the diagnosis of PD and
neurodegenerative parkinsonisms. RT-QuIC analyses of OM and cerebrospinal fluid (CSF) can be combined with the
aim of increasing the overall diagnostic accuracy of these diseases, especially in the early stages.
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Background
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder after Alzheimer’s disease (AD)
and is characterized by bradykinesia with rigidity, tremor
and postural instability [1, 2]. Neurodegenerative parkin-
sonisms resemble PD in some of its clinical feature and
include Multiple System Atrophy (MSA), Progressive
Supranuclear Palsy (PSP) and Corticobasal Degeneration
(CBD) [3, 4]. Although highly heterogeneous from a clin-
ical and neuropathological point of view, all these diseases
share a common pathological mechanism that involves
the accumulation of abnormally folded proteins in the
Central Nervous System (CNS) [5, 6]. In particular, PD is
characterized by the presence of α-synuclein aggregates in
neuronal perikarya and neuronal process (referred to as
Lewy bodies and Lewy neurites) mainly located in the
brainstem, while neurodegenerative parkinsonisms can be
divided in two molecular classes [7, 8]. The first molecular
class corresponds to MSA that is characterized by accu-
mulation of abnormal conformers of α-synuclein (also
referred to as α-synucleinopathies) in oligodendrocytes of
cerebellum, pons and basal ganglia [3, 9–11]. The second
molecular class includes disorders characterized by brain
accumulation of abnormal forms of tau protein which
cause PSP or CBD (hence referred to as tauopathies). PSP
shows aggregates of 4-repeat tau (4R) in neurons (neuro-
fibrillary tangles), astrocytes (tufted astrocytres) and oligo-
dendrocytes (coiled bodies) prevalently located in basal
ganglia and brainstem, while CBD is characterized by the
presence of 4R tau in oligodendrocytes (coiled bodies),
astrocytes (astrocytic plaques), and neurons located in
neocortex and basal ganglia [3]. One of the most
intriguing aspects of these diseases is therefore the fact
that the same protein might account for different patholo-
gies. Probably this is due to conformation-dependent
changes in the protein affected. Indeed, either α-synuclein
or tau can acquire different abnormal conformations, that
can be considered analogous to the “strains” of prion dis-
eases [3, 12–17]. It can be hypothesized that different
strains of α-synuclein are responsible for PD or MSA
while different strains of tau cause PSP or CBD. These
structural differences might dictate specific tropism of
these proteins for defined neuroanatomical regions or
even cell types. Currently, both α-synuclein and tau are
considered disease-specific biomarkers and definite diag-
nosis of PD and neurodegenerative parkinsonisms relies
on their identification and anatomical distribution in
brains collected at autopsy. Conversely, the in vivo diagno-
ses based on clinical criteria and neuroimaging are charac-
terized by unsatisfactory sensitivity and specificity, and
several cases might be misdiagnosed, especially in the
early stages when clinical symptoms overlap [18–20].
Moreover, in some instances, the co-occurrence of differ-
ent protein aggregates may take place in the brain. For
instance, cases of PSP, CBD and AD confirmed at neuro-
pathological level, were found to concurrently contain ag-
gregates of α-synuclein in the form of Lewy bodies or, in
other cases, aggregates of α-synuclein in isolation may
phenotypically present as PSP or CBD [21–25]. Similarly,
cases of MSA or PD were found to also contain aggre-
gated species of tau [26–29]. The in vivo diagnostic accur-
acy for PD is at about 80 and 20% of patients classified as
probable PD are indeed misdiagnosed [19]. Even worse,
only 26% of patients with a diagnosis of possible PD are
confirmed at autopsy [30]. The diagnostic accuracy of
MSA is even lower and the clinical diagnosis is confirmed
at autopsy in only 62% of patients [31–34]. Diagnostic ac-
curacy of PSP has a specificity of about 95% for probable
and 80–93% for possible cases [35–39] while only the 68%
of patients diagnosed in vivo as CBD are confirmed at aut-
opsy [40]. Therefore, a defined discrimination of these dis-
eases is difficult with the current clinical diagnostic
criteria alone. Compelling evidence suggests that trace
amount of these abnormally folded proteins are present in
cerebrospinal fluid (CSF) and peripheral tissues of dis-
eased patients. Unfortunately, their concentration is well
below the limits of detection of the conventional diagnos-
tic techniques. By exploiting an innovative technique
named Real Time Quaking Induced Conversion assay
(RT-QuIC), developed in the field of prion diseases [41,
42], it was recently shown the presence of minute amount
of abnormal α-synuclein in the CSF of PD patients with
95% sensitivity and 100% specificity [43]. Similarly, Soto
and colleagues successfully identified α-synuclein in the
CSF of patients with PD with 89% sensitivity and 97%
specificity [44]. More recently, Groveman improved the
assay and allowed quantitation of α-synuclein present in
the CSF of patients with PD and Dementia with Lewy
bodies (DLB) [45]. Finally, Saijo and colleagues showed
the presence of abnormal 3R-tau in the CSF of patients
with Frontotemporal dementia (FTLD) [46] with 100%
sensitivity and 94% of specificity. Therefore, RT-QuIC rep-
resents a fundamental tool that might significantly in-
crease the diagnostic accuracy of these diseases. The
technique exploits the prion-like properties of abnormally
folded α-synuclein and tau proteins, which become
capable of interacting with their normal counterparts
forcing them to acquire similar pathological structures.
While in vivo this feature is considered to be responsible
of the progression of α-synuclein or tau pathology within
the brain (by transmission of protein misfolding), in vitro
this property has been exploited in RT-QuIC for detecting
minute amount of abnormally folded proteins in a known
biological samples (CSF or blood or urine) [47–56]. In
RT-QuIC, samples are incubated with a recombinant
protein used as substrate of reaction. The presence of
pathological proteins in the samples triggers the aggrega-
tion of the substrate, generating amyloid fibrils whose
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formation is monitored in real time with the use of the
Thioflavin-T (ThT) fluorescent dye [57, 58]. Recent
evidence has demonstrated that abnormal α-synuclein or
tau proteins can accumulate in the olfactory epithelium
collected post-mortem from patients with AD [59]. To the
best of our knowledge, there are no reports that have
evaluated the ability of RT-QuIC to detect trace amount
of abnormally folded proteins in OM samples collected
from patients with a clinical diagnosis of PD or neurode-
generative parkinsonisms. RT-QuIC has been successfully
optimized for the analysis of OM samples collected from
patients with prion diseases, so far [60]. We therefore
decided to perform RT-QuIC experiments, using human
recombinant α-synuclein (rec-αS) as reaction’s substrate,
aimed at evaluating the presence of abnormal α-synuclein
in OM samples collected from a consecutive series of
patients affected by different neurodegenerative parkin-
sonian syndromes, to evaluate if seeding activity for α-sy-
nuclein can differentiate between synucleinopathies and
tauopathies. Moreover, we evaluated if different strains of
α-synuclein (MSA or PD) might have imprinted their ab-
errant structure to the same rec-αS used as RT-QuIC sub-
strate. In contrast to the widely used CSF, OM samples
can be periodically collected with a non-invasive proced-




This is a cross sectional observational study. A consecu-
tive series of patients affected by neurodegenerative par-
kinsonisms were selected (Additional file 1: Table S1).
Patients were eligible for enrollment if they had a diag-
nosis of idiopathic PD according to the Hughes and Pos-
tuma criteria [18, 61], MSA according to the Gilman
criteria [33], PSP according to the Höglinger criteria [39]
and CBD according to the Armstrong criteria [62]. Sam-
ples of olfactory mucosa were collected from each
patients following well established procedure (referred to
as “nasal brushing”) [63] which is shown at this link
https://www.youtube.com/watch?v=wYb9W3u6uMY and
described below. We selected only patients whose diag-
nosis was characterized by the highest clinical level of
certainty.
Expression and purification of human recombinant α-
synuclein
Human recombinant α-synuclein (rec-αS) was cloned
and expressed in pET-11a vector, using BL21 (DE3) E.
coli strain. The expression of the protein was obtained
by growing cells in Luria-Bertani broth medium with
100 mg/mL ampicillin at 37 °C, until an Optical density
of about 0.6 at 600 nm, followed by induction with 0.6
mM isopropyl β-D-thiogalactoside (IPTG) for 5 h. The
protein was subsequently extracted from bacterial
periplasm by osmotic shock and boiling. Briefly, the cell
pellet was incubated in osmotic shock buffer (30 mM
Tris pH 7.2, 2 mM EDTA, 40% sucrose), followed by
centrifugation (9000 rpm, 30min) and boiling for 10
min. After two steps of ammonium sulfate precipitation
(35 and 55%) the protein was purified by anion exchange
chromatography (HiTrap column, GE Healthcare).
AKTA purification systems (GE Healthcare) were used
for monitoring the protein absorbance during chroma-
tography process. The presence of rec-αS was monitored
during all the purification steps by gel electrophoresis
(SDS-PAGE). The identity and the purity of the final
product was confirmed by Western blotting and mass
spectroscopy. Fractions containing α-synuclein were
dialyzed into water, quantified by measuring absorbance
at 280 nm, lyophilized (FreeZone 2.5 Freeze Dry System,
Labconco) and stored at − 80 °C. Before use, rec-αS was
dissolved in H2O (at the final concentration of 5 mg/mL)
and used to prepare the reaction mix.
In vitro generation of recombinant α-synuclein
aggregates
Rec-αS was diluted in a reaction mix composed of 40mM
PBS (pH 8.0), 170mM NaCl and 10 μM Thioflavin-T
(ThT) at the final concentration of 140 μM. Reactions
were performed in triplicate in a black 96-well optical flat
bottom plate (Thermo Scientific). Each well was supple-
mented with 100 μL of reaction mix. The plate was sealed
with a sealing film (Thermo Scientific), inserted into a
Fluoroskan Ascent microplate reader (Thermo Scientific)
and subjected to cycles of shaking (1min at 600 rpm,
single orbital) and incubation (14min at 42 °C). The
addition of a 3-mm glass bead (Sigma) was required to
sustain protein aggregation. The presence of protein
aggregates was confirmed by means of ThT analysis,
Western blot and Transmission Electron Microscopy
(TEM) analyses.
Preparation of brain samples for biochemical and RT-
QuIC analyses
Frontal cortices of patients with neuropathologically con-
firmed diagnoses of Frontotemporal Dementia with par-
kinsonism-17 associated with P301L tau mutation (FTDP-
17, n = 1), Progressive Supranuclear Palsy (PSP, n = 1),
Corticobasal Degeneration (CBD, n = 1) and Non Demen-
ted Patient (NDP, n = 1); pons of patient with neuropatho-
logically confirmed diagnosis of Parkinson’s disease (PD,
n = 1); cerebellum of patient with neuropathologically
confirmed diagnosis of Multiple System Atrophy (MSA,
n = 1) were homogenized in PBS (pH 7.4, Sigma) at 10%
(weight/volume), using a glass potter homogenizer. Sam-
ples were centrifuged (Eppendorf Centrifuge) at 800 × g,
for 1 min at 4 °C, in order to remove cellular debris.
De Luca et al. Translational Neurodegeneration            (2019) 8:24 Page 3 of 14
Supernatants were collected and stored at − 20 °C for fur-
ther biochemical and RT-QuIC analyses. For RT-QuIC
analysis, serial dilutions of PD, MSA and FTDP-17 brain
homogenates [10-3, 10-6 and 10-9] were prepared in PBS.
Extraction of soluble and insoluble α-synuclein from
brains
Extraction of soluble and insoluble α-synuclein fractions
from brains was performed as previously described [64].
Briefly, approximately 0.3 g of frozen brain tissues were
homogenized 10% (weight/volume) in TBS buffer
(supplemented with protease inhibitors and phosphatase
inhibitors), using a Tissue Lyser (Qiagen) with a steel
bead, for 1min at maximum speed. The homogenate was
then clarified by centrifugation at 1000 x g for 5min at
4 °C. Supernatants were transferred to polycarbonate cen-
trifuge tubes and centrifuged at 100000 x g (Beckman
Coulter Optima MAX) for 1 h at 4 °C. Resulting superna-
tants were collected as TBS-soluble fraction (soluble α-sy-
nuclein) while pellets were washed with 5 volumes of TBS
and centrifuged at 100000 x g for 15min at 4 °C. Pellets
were then suspended in TBS buffer supplemented with
SDS (5% final dilution) and sonicated (8min at 500W).
Final solution was centrifuged at 100000 x g for 30min at
25 °C. Supernatant was collected as SDS soluble fraction
(detergent-soluble α-synuclein) while pellets were washed
with 5 volumes of TBS-SDS buffer and centrifuged at
100000 x g for 15min at 25 °C. Pellets were then sus-
pended in 50 μL of TBS-SDS buffer supplemented with
urea (8M final concentration), sonicated for 5min at 500
W, diluted 1:1 with TBS buffer and collected as urea sol-
uble fraction (insoluble α-synuclein).
SDS-PAGE and Western blotting
Brain extracts containing either soluble or insoluble α-
synuclein were supplemented with LDS loading buffer,
heated at 100 °C for 10 min and loaded into 12% Bolt
Bis-Tris Plus gels (Invitrogen). Proteins were separated
by means of SDS-PAGE and then transferred onto
Polyvinylidene difluoride (PVDF) membranes (Immobi-
lon-P, Millipore) and incubated with 5% (weight/volume)
non-fat dry milk (prepared in Tris-HCl with 0.05%
Tween-20) for 1 h at room temperature under shaking.
PVDF membranes were incubated with primary anti-
body to α-synuclein (polyclonal AS08 358 Agrisera: epi-
topes 1–15) overnight at 4 °C under shaking.
RT-QuIC products were digested with proteinase K (see
section PK digestions) and analyzed by Western blot
following the same procedures described above. In this
case, PVDF membranes were incubated with primary anti-
bodies directed against different epitopes of α-synuclein
(monoclonal 4D6 Invitrogen: epitopes 124–134 [65]; poly-
clonal AB5038 EMD Millipore: epitopes 111–131 [66];
monoclonal 5C2 Novus Biologicals: epitopes 61–95 [67];
polyclonal AS08 358 Agrisera: epitopes 1–15 [68]) over-
night at 4 °C under shaking. Membranes were incubated
with appropriate secondary antibodies conjugated with
horseradish peroxidase (GE) and developed with chemilu-
minescent system (ECL Prime). Reactions were visualized
using a G:BOX Chemi Syngene system.
Collection of olfactory mucosa samples and preparation
for RT-QuIC analyses
A total of 47 samples of olfactory mucosa (OM) were
collected from: 18 patients with a clinical diagnosis of PD
[18, 61], 11 patients with a clinical diagnosis of MSA [31],
6 patients with a clinical diagnosis of CBD [62] and 12
patients with a clinical diagnosis of PSP [37]. Before
collection, the nasal cavity was treated with a topical
anesthetic (Ecocain, Molteni Dental) for 10min and, with
the use of a special cotton swab (referred to as brush,
FLOQSwabsTM Copan Italia, Brescia, Italy), OM were
collected from the medial septal wall just above the mid-
dle turbinate, as previously described [63, 69]. After col-
lection, cotton swabs were immersed in saline solution
and olfactory cells separated from the brushes by means
of vortexing. Cells were finally pelleted at 800 × g for 20
min at 4 °C. The supernatants were removed, and approxi-
mately 6 μg of the pellets were collected with the use of
inoculating loops. Such material was then transferred into
a tube containing 50 μL of PBS and used for RT-QuIC
analyses.
RT-QuIC analysis of in vitro generated α-synuclein
aggregates
The solution containing in vitro generated α-synuclein
aggregates was sonicated for 3 min at 500W and serially
diluted (from 10− 1 to 10− 12 volume/volume) in its own
reaction buffer. Five μL of the following dilutions: un-
diluted, 10− 3, 10− 6, 10− 9, 10− 12 was added to 95 μL of
reaction mix and subjected to RT-QuIC analysis. Reac-
tion mix was composed as follow: rec-αS diluted in 40
mM PBS (pH 8.0), 170mM NaCl and 10 μM Thioflavin-
T (ThT) at the final concentration of 140 μM. All re-
agents used for the preparation of the reaction mix were
filtered through a 0.22 μm filter before the addition of α-
synuclein aggregates. All RT-QuIC reactions were per-
formed in triplicate in a black 96-well optical flat bottom
plate (Thermo Scientific) using the Fluoroskan Ascent
microplate reader (Thermo Scientific). Samples under-
went to cycles of shaking (1 min at 600 rpm, single
orbital) and incubation (14 min at 42 °C). Fluorescent
intensities, expressed as arbitrary units (AU), were taken
every 30 min using 450 ± 10 nm (excitation) and 480 ±
10 nm (emission) wave-lengths, with a bottom read. The
addition of a 3-mm glass bead (Sigma) was necessary to
sustain protein aggregation.
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RT-QuIC analysis of brain homogenates
Brain homogenates (BH) collected from patients with
PD, MSA, PSP, CBD, FTDP-17 and NDP were diluted at
10− 3 volume/volume in PBS. Samples were sonicated (3
min at 500W) and 2 μL was then supplemented to
98 μL of RT-QuIC reaction mix prepared as follow: rec-
αS diluted in 40mM PBS (pH 8.0), 170 mM NaCl and
10 μM ThT at the final concentration of 70 μM. Reac-
tions were performed in triplicate in a black 96-well
optical flat bottom plate (Thermo Scientific). Each well
contained 100 μL of final reaction’s volume. The plate
was sealed with a sealing film (Thermo Scientific),
inserted into a Fluoroskan Ascent microplate reader
(Thermo Scientific) and subjected to cycles of shaking
(1 min at 600 rpm, single orbital) and incubation (29 min
at 42 °C). Fluorescent intensities, expressed as arbitrary
units (AU), were taken every 30 min using 450 ± 10 nm
(excitation) and 480 ± 10 nm (emission) wave-lengths,
with a bottom read. The addition of a 3-mm glass bead
(Sigma) was required to promote protein aggregation. A
sample was considered “capable of seeding α-synuclein
aggregation” if at least 2 out 3 replicates crossed a
threshold of fluorescence set at 500 AU. We have then
calculated the average fluorescence intensity of the two
or three replicates that crossed this threshold and plot-
ted resulting values in a graph against time. If only one
(or none) of the replicates crossed the threshold, we
considered the sample as “incapable of seeding α-synu-
clein aggregation” and we calculated the average fluores-
cence intensity of the two (or three) replicates that
remained below such threshold.
RT-QuIC analysis of olfactory mucosa samples
After preparation (as previously described), 2 μL of OM
samples was added to 98 μL of RT-QuIC reaction mix
which was prepared as follow: rec-αS diluted in 40mM
PBS (pH 8.0), 170mM NaCl and 10 μM Thioflavin-T
(ThT) at the final concentration of 140 μM. Reactions
were performed in triplicate in a black 96-well optical
flat bottom plate (Thermo Scientific). Each well con-
tained 100 μL of final reaction’s volume. The plate was
sealed with a sealing film (Thermo Scientific), inserted
into a Fluoroskan Ascent microplate reader (Thermo
Scientific) and subjected to cycles of shaking (1 min at
600 rpm, single orbital) and incubation (14 min at 42 °C).
Fluorescent intensities, expressed as arbitrary units
(AU), were taken every 30min using 450 ± 10 nm (exci-
tation) and 480 ± 10 nm (emission) wave-lengths, with a
bottom read. The addition of a 3-mm glass bead (Sigma)
was required to promote protein aggregation. A sample
was considered “capable of seeding α-synuclein aggrega-
tion” if at least 2 out 3 replicates crossed a threshold of
fluorescence set at 6 AU within a certain period of time
set at 120 h. We have then calculated the average
fluorescence intensity of the two or three replicates that
crossed this threshold of fluorescence and plotted result-
ing values in a graph against time. If only one (or none)
of the replicates crossed the threshold, we considered
the sample as “incapable of seeding α-synuclein aggrega-
tion” and we calculated the average fluorescence inten-
sity of the two (or three) replicates that remained below
such threshold.
PK digestion assays
Proteinase K (PK) was used to perform limited proteo-
lytic digestion of the final RT-QuIC products (after seed-
ing with brain homogenates or OM samples). In
particular, samples were treated with PK 100 μg/mL at
37 °C for 60 min under shaking (500 rpm). Digestions
were stopped by the addition of LDS loading buffer and
boiling at 100 °C for 10 min. Western blot analyses were
then performed.
Transmission electron microscopy analyses
Ten μL of RT-QuIC products was dropped onto 200-
mesh Formvar-carbon coated nickel grids for 30 min
and the remaining drop was blotted dry using filter
papers. The grids were subsequently stained with 25%
Uranyl Acetate Replacement (UAR, negative staining)
for 10 min, the solution was removed using filter papers
and the grids were air-dried for 15 min before the ana-
lyses. Images were recorded at 120 kV with a FEI Tecnai
Spirit, equipped with an Olimpus Megaview G2 camera.
Statistical analyses
TEM images were analyzed with the Gwyddion software
for measuring the distances between over-twists occurring
in the same amyloid fibril. Final values were compared
with a double-tailed unpaired t-test (Mann-Whitney U
test) performed using the Prism software (GraphPad v5.0).
Graphic representations of RT-QuIC kinetics (based on
ThT signals) were also obtained with the Prism software
(GraphPad v5.0). Densitometric analysis of PK resistant
RT-QuIC products was performed using ImageJ software
(v1.48) and final values were compared using a double
tailed unpaired t-test (Mann-Whitney U test).
Results
In vitro generated α-synuclein aggregates efficiently
seeded RT-QuIC reaction
The kinetics of rec-αS aggregation was reproducible over
time and with different batches of protein. Particularly,
after a lag phase of about 40 h there was a rapid increas-
ing in ThT signal that reached a plateau at around 100 h
(Fig. 1a). TEM analysis of the products collected after
100 h confirmed the presence of α-synuclein aggregates,
mostly in the form of amyloid fibrils (Fig. 1b). These
aggregates were used as artificial seeds. In particular,
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they were serially diluted and added at the beginning of
RT-QuIC assays performed using fresh rec-αS as reac-
tion’s substrate. Results of these experiments are shown
in Fig. 1c and clearly demonstrate that even the lowest
dilution (which extrapolates to approximately 1 attogram
of aggregated protein) was able to efficiently accelerate
the kinetics of rec-αS aggregation mostly in a dose-
dependent manner.
Brain homogenates of patients with synucleinopathies
efficiently seeded RT-QuIC reaction
Considering the high level of RT-QuIC sensitivity in
detecting extremely low amounts of artificial seeds,
we decided to verify its ability to detect pathological
α-synuclein aggregates present in brain samples of pa-
tients with PD and MSA. Firstly, we have demon-
strated the presence of α-synuclein aggregates in the
brain of PD and MSA by means of Western blot. To
this aim, brains of patients with MSA, PD, PSP, CBD,
FTDP-17 and NDP were subjected to serial steps of
high-speed centrifugation in order to separate soluble
and insoluble (mostly aggregated) α-synuclein species.
Subsequently, Western blot analyses confirmed the
presence of aggregated forms of α-synuclein (urea-
fraction) only in brain homogenates of patients with PD
and MSA. No aggregates were detected in brain of pa-
tients with FTDP-17, PSP, CBD and NDP (Fig. 2a). There-
fore, the same brain homogenates (10− 3 dilution) were
analyzed by means of RT-QuIC. As shown in Fig. 2b, all
brain samples were able to increase the kinetics of rec-αS
aggregation with those of PD and MSA being character-
ized by higher fluorescence intensities (always above 1000
AU) compared to PSP, CBD, FTDP-17 and NDP (that
never crossed 500 AU). Thus, considering a threshold
of 500 AU we could identify brain homogenates of pa-
tients with PD and MSA. Since the amount of patho-
logical α-synuclein eventually present in OM samples
of PD and MSA patients is much lower than that
present in the 10− 3 dilution of brain homogenates pre-
viously tested by means of RT-QuIC, we have per-
formed additional experiments using lower dilutions
[10-6 and 10-9] of PD and MSA samples. These
dilutions were estimated to contain picograms [10-3],
femtograms [10-6] and attograms [10-9] of pathological
α-synuclein. As shown in Fig. 2c, all of them efficiently
increased the kinetics of rec-αS aggregation. Notably,
dilutions of FTDP-17 brain homogenates were used as
controls and promoted rec-αS aggregation with less
a b
c
Fig. 1 RT-QuIC analysis of in vitro generated α-synuclein aggregates. a In vitro generation of α-synuclein aggregates (artificial seeds). rec-αS [140 μM]
was induced to aggregate by alternating cycles of incubation and shaking. Average ThT fluorescence intensity was plotted against time; b TEM
analysis of final α-synuclein aggregates. Amyloid fibrils were efficiently generated in vitro under well controlled experimental conditions. Scale bar: 500
nm; c Assessment of the RT-QuIC detection limits. Serial dilutions of the artificial seeds previously produced were analyzed by means of RT-QuIC. All
dilutions efficiently accelerated the kinetics of rec-αS aggregation. Average ThT fluorescence intensity was plotted against time. Self-assembly refers to
unseeded rec-αS reactions
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efficiency and lower fluorescence intensity (lower than
500 AU) than those of PD and MSA.
Analysis of final RT-QuIC products seeded with different
brain homogenates did not show biochemical differences
Being aware of the fact that different strains of α-synuclein
(responsible for PD and MSA) [70] could force the same
substrate to acquire distinct abnormal conformations, we
decided to perform biochemical analysis of the final reac-
tion products. In particular, RT-QuIC products seeded with
PD, MSA and FTDP-17 brain homogenates were digested
with PK and analyzed by means of Western blot. Regardless
of the brain homogenate used to seed the reaction, all α-sy-
nuclein aggregates showed similar electrophoretic mobility
and banding profile. Therefore, PK digestion alone was not
able to demonstrate whether different seeds could imprint
their specific conformations to rec-αS. Although character-
ized by low fluorescence intensity, also FTDP-17 brain
homogenate revealed the presence of PK-resistant α-synu-
clein aggregates whose biochemical profile was similar to
those of PD and MSA (Additional file 2: Figure S1a).
Olfactory mucosa (OM) samples of patients with clinical
diagnosis of PD or MSA efficiently seeded RT-QuIC
reaction
OM samples collected from patients with a clinical diag-
nosis of PD (n = 18), MSA (n = 11), CBD (n = 6) and PSP
(n = 12) (see Additional file 1: Table S1 for details) were
blindly analyzed by means of RT-QuIC to investigate
their effects on the kinetics of rec-αS aggregation. Ac-
cording to the thresholds of time (120 h) and fluores-
cence intensity (6 AU) set as described in materials and
methods, we have found that 10 out of 18 samples of PD
and 9 out of 11 samples of MSA were able to efficiently
accelerate rec-αS aggregation (Fig. 3a). Similarly, 1 out
of 6 samples of patients with CBD and 2 out of 12
samples of patients with PSP were able to trigger rec-αS
aggregation. Hence, we have observed α-synuclein seed-
ing activity in 19 out of 29 samples belonging to patients
with probable α-synuclein pathology but also in 3 out of
18 samples belonging to patients with probable tauopa-
thies (see Table 1). This may be due to the fact that CBD
or PSP can be caused by distinct abnormal conformers
of tau (strains) able to cross-seed the aggregation of α-
a b
c
Fig. 2 RT-QuIC analysis of brain homogenates of patients with PD and neurodegenerative parkinsonisms. a Extraction of soluble and insoluble
α-synuclein fractions from brain homogenates of patients with PD, MSA, PSP, CBD, FTDP-17 or NDP control. Western blot analyses confirmed the
presence of insoluble α-synuclein only in PD and MSA samples. Blots were immunostained with the AS08 358 antibody. Numbers in the right
indicate the position of molecular weights. Asterisks indicate unspecific binding. b RT-QuIC analysis of BH samples. Two μL of sonicated BH
collected from PD, MSA, PSP, CBD, FTDP-17 and NDP patients was added to rec-αS substrate and analyzed by means of RT-QuIC. PD and MSA
samples efficiently induced rec-αS aggregation that reached higher levels of fluorescence intensities compared to those of PSP, CBD, FTDP-17
and NDP. Average ThT fluorescence intensity was plotted against time. c Assessment of the RT-QuIC detection limits. Serial dilutions (undiluted,
10− 3, 10− 6, 10− 9) of sonicated BH collected from PD, MSA and FTDP-17 subjects were analyzed by means of RT-QuIC. All dilutions efficiently
induced rec-αS aggregation but those of FTDP-17 were characterized by lower fluorescence intensities compared to those of PD and MSA.
Average ThT fluorescence intensity was plotted against time
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synuclein with different efficiency. Otherwise, such seed-
ing activity might suggest that these diseases have been
misdiagnosed or they might have been correctly diag-
nosed but characterized by an incidental Lewy body
deposition.
Notably, we did not find any correlation between posi-
tive RT-QuIC results and other clinical evaluations
(especially disease-duration and age at disease onset)
(Additional file 1: Table S1).
OM samples of PD or MSA patients induced the
formation of α-synuclein aggregates characterized by
different biochemical features
Aggregated products resulting from RT-QuIC reactions
seeded with OM samples of PD or MSA were collected
at the end of the reaction and subjected to PK digestion
(100 μg/mL) for 60 min at 37 °C. Digested samples where
then analyzed by means of Western blot with the use of
antibodies directed against different epitopes (C-ter-
minal, Non-Amyloid-β Component (NAC) core and N-
terminal part) of the protein (Additional file 2: Figure
S1c). This enabled us to demonstrate that PK treatment
efficiently removed the C-terminal part of the protein,
while leaving a more resistant core composed of the
NAC region and the most N-terminal part of α-synu-
clein, spanning from residues 1 to 15. Western blot ana-
lyses with anti NAC antibody (5C2) did not provide
informative data other than demonstrating the presence
of a PK resistant core. In contrast, analyses with anti-
body against the most N-terminal part of the protein
demonstrated the presence of important and reprodu-
cible differences between samples seeded with olfactory
mucosa of PD or MSA patients. In general, we have





Fig. 3 RT-QuIC analysis of OM samples collected from patients with PD and neurodegenerative parkinsonisms. a Kinetics of rec-αS aggregation
after the addition of OM samples. Two μL of OM collected from PD (n = 18), MSA (n = 11), CBD (n = 6) and PSP (n = 12) was added to rec-αS
substrate and analyzed by means of RT-QuIC. 10/18 samples of PD, 9/11 samples of MSA, 1/6 sample of CBD and 2/12 samples of PSP induced
the aggregation of the substrate. Average ThT fluorescence intensity was plotted against time. b Biochemical analyses of RT-QuIC products of OM
samples collected from PD and MSA patients that induced rec-αS aggregation (representative image). Ten μL of final RT-QuIC products were
digested with PK and analyzed by means of Western blot. Green arrows indicate peculiar bands of RT-QuIC products seeded with PD samples.
One band migrating at around 6–8 kDa is found in these samples. Orange arrows indicate peculiar band of RT-QuIC products seeded with MSA
samples. Two bands are detected at around 6–8 kDa and a third band is detected at around 22 kDa. Blots were immunostained with the AS08
358 antibody. One asterisk (*) indicates the presence of aggregated species of α-synuclein, while two asterisks (**) indicate partially digested
protein. Numbers in the right indicate the position of molecular weights. Dashed lines indicate cropped images from separate gels. c Biochemical
analyses of RT-QuIC products of OM samples collected from PD, MSA, CBD and PSP patients that did not induce rec-αS aggregation. Ten μL of
final RT-QuIC products were digested with PK and analyzed by means of Western blot and revealed the lack of PK-resistant bands. Blots were
immunostained with the AS08 358 antibody. Numbers in the right indicate the position of molecular weights. d Densitometric analysis of RT-
QuIC products seeded with PD (n = 4) or MSA (n = 4) samples. Three replicates per sample were subjected to PK treatment (100 μg/mL, 37 °C, 60
min) and immunostained with the AS08 358 antibody before quantification. This analysis confirmed that differences in PK resistance between PD
and MSA samples were statistically significant (p = 0.0061)
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products seeded with MSA samples compared to those
seeded with PD. Densitometric analysis performed in
triplicate on 4 PD and 4 MSA seeded samples confirmed
that these differences were statistically significant (p =
0.0061) (Fig. 3d). Additionally, samples seeded with PD
were characterized by the presence of a PK-resistant
band migrating between 6 and 8 kDa, while samples
seeded with MSA showed three PK-resistant bands, two
migrating between 6 and 8 kDa, and a third one migrat-
ing at around 22 kDa (Fig. 3b). OM that did not induce
α-synuclein aggregation, comprising some cases of PD
or MSA and almost all PSP and CBD samples, were
completely digested by PK and did not show any resist-
ant band (Fig. 3c). Some PSP and CBD samples induced
α-synuclein aggregation and their biochemical profile is
reported in (Additional file 2: Figure S1b). In this case,
both PSP and the CBD samples showed a PK-resistant
α-synuclein banding profile typical of those observed in
MSA seeded reactions.
OM samples of PD or MSA patients induced the
formation of α-synuclein aggregates characterized by
different structural features
Biochemical data were integrated with TEM analysis with
the aim of verifying whether the differences in PK-resist-
ant fragments were paralleled by morphological differ-
ences. Thus, we have analyzed the structural features of
aggregated α-synuclein obtained at the end of the RT-
QuIC assays seeded either with OM samples of PD (n = 5)
or MSA (n = 5) patients. Shape, number and the length of
fibrils were analyzed, with special focus on the presence
and the distance between consecutive over-twists present
in the same fibril. In total, we have analyzed the distance
of over-twists present in 50 fibrils per patient, reaching a
total number of 250 fibrils per pathology. These data were
pooled together for each pathology (PD or MSA) and
showed that the same α-synuclein substrate was surpris-
ingly able to acquire different structural features when
seeded with two distinct strains of α-synuclein. In particu-
lar, we have observed that the distance between over-
twists in α-synuclein fibrils obtained from RT-QuIC
products seeded with OM of MSA patients was about
142 ± 1.3 nm (mean ± standard error of the mean) while
that of PD patients was shorter and about 131 ± 1.1 nm
(Fig. 4a and b) and such differences were statistically sig-
nificant (p < 0.0001, Mann-Withney U test). More inter-
estingly, such differences were reproducible over time and
within pathologies.
We have finally analyzed the RT-QuIC aggregates
induced by some PSP or CBD samples and observed that
the distance between over-twists was different from
those of MSA or PD samples. In particular, those of PSP
patients were at about 155 ± 1.5 nm, while those of CBD
were at about 115 ± 1.7 nm (Additional file 3: Figure S2).
Discussion
Definite diagnosis of PD or other neurodegenerative par-
kinsonisms is extremely challenging especially in the
Table 1 Clinical data and OM/RT-QuIC results of all patients included in the study
PD MSA CBD PSP
Clinical criteria (ref.) [18, 61] [33] [62] [39]
Number of patients 18 11 6 12
Age at time of evaluation (years) 64.2 ± 7.8 62.3 ± 9.2 63.3 ± 10.6 68.3 ± 7.0
Age at disease onset (years) 52.4 ± 6.1 56.5 ± 9.5 60.2 ± 10.9 64.3 ± 8.2
Disease duration (years) 10.1 ± 5.1 5.8 ± 3.4 3.2 ± 1.6 4.0 ± 3.6
Gender (F/M) 8/10 5/6 4/2 5/7
Frequency of symptoms (%)
• Rigid akinetic parkinsonism 100 90.1 83.3 91.7
• Tremor 88.9 81.8 50 8.3
• Ataxia 0 90.1 50 91.7
• Apraxia 0 0 100 33.3
• Delusions 16.7 9.1 0 8.3
• Dementia 11.1 0 16.7 58.3
• Psychiatric disorders 33.3 45.5 33.3 50
• REM behavioural disorder 55.6 63.6 0 0
• Autonomic impairment 83.3 100 33.3 16.7
RT-QuIC seeding activity for α-synuclein
(% in total patients)
10 (56%) 9 (82%) 1 (16%) 2 (16%)
Values of continuous variables are presented as mean ± standard deviation (SD)
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early stages of the disease when symptoms might over-
lap. These diseases are characterized by intracerebral
accumulation of disease-specific abnormally folded pro-
teins: α-synuclein in the case of PD and MSA, tau in the
case of PSP and CBD. This process begins decades
before the appearance of clinical signs of the disease. It
is therefore conceivable that the abnormal proteins accu-
mulate also in peripheral tissues and body fluids (e.g.
olfactory mucosa, blood and urine) long before disease
onset at concentrations well below the detection limits
of the classical biochemical diagnostic techniques. In the
last few years, an innovative technique, named RT-QuIC,
has been developed in the field of prion diseases and en-
abled the detection of trace amounts of prions in CSF
and peripheral tissues, in particular olfactory mucosa
and skin samples with high levels of sensitivity and spe-
cificity [71]. Therefore, RT-QuIC has been proposed as
diagnostic tool for prion diseases. Recently, it has been
extended to the analysis of CSF samples collected from
patients with other neurodegenerative disorders, includ-
ing PD, DLB, AD and FTLD [43–46, 72]. Although with
lower sensitivity and specificity compared to those
reached in the field of prion diseases, RT-QuIC has
successfully shown the presence of abnormal forms of α-
synuclein, tau and Aβ in the CSF of PD or DLB, FTLD
and AD patients.
Starting from these observations, we decided to
optimize the RT-QuIC for the analysis of OM samples
collected from patients with a clinical diagnosis of PD
and MSA. As comparison, we have included OM
samples from patients with clinical diagnosis of neurode-
generative parkinsonisms associated with tau pathology,
i.e. PSP and CBD. Although data are currently available
about RT-QuIC analysis for detecting abnormal α-synu-
clein in CSF [43–45] the study of OM samples might
widen the diagnostic approach to these diseases by the
analysis of tissues that can be collected by less invasive
procedures.
The RT-QuIC analyses performed on α-synuclein
are still in their embryonic phases and require further
steps of standardization, reproducibility controls and
harmonization before even thinking of introducing
them as a diagnostic procedure. The main objective
of our study was to verify whether OM collected
from patients with PD and MSA have a different be-
havior as seeding activity for α-synuclein compared to
patients with tauopathies.
First of all, we have set up the protocol of rec-αS
aggregation and verified the ability of α-synuclein aggre-
gates either artificially produced (referred to as artificial
seeds) or present in brain samples to accelerate this
kinetics. Our results showed an acceleration of rec-αS
aggregation after the addition of attograms of artificial
seeds, thus indicating that RT-QuIC is highly sensitive.
The kinetics was also accelerated by the addition of PD,
MSA, PSP, CBD, FTDP-17 and NDP brain homogenates,
however the fluorescence intensities were significantly
higher in reactions seeded with PD or MSA compared
to the others. These data suggest that the homologous
seeding (ability of abnormally folded α-synuclein to
accelerate the aggregation of rec-αS) is more effective
than the heterologous one where the kinetics of rec-αS
aggregation could have been modified by proteins other
than α-synuclein. This phenomenon is also known as
cross-seeding effect and, for instance, abnormal forms of
tau present in PSP, CBD and FTDP-17 samples could
have contributed in stimulating rec-αS aggregation.
Similarly, other proteins present in NDP sample might
have sustained a cross-seeding effect. Since RT-QuIC
analyses of brain homogenates enabled us to identify PD
and MSA samples, we decided to verify whether this dis-
crimination could also occur in RT-QuIC reactions
seeded with OM collected from patients with clinical
diagnosis of PD, MSA, PSP and CBD.
Compared to brains, where a faint cross-seeding effect
often occurred, OM analysis produced much clear re-
sults. Probably OM samples contained fewer proteins or
a b
Fig. 4 Representative TEM images of RT-QuIC products seeded with
OM samples derived from PD and MSA patients. a Measurements of
the distance between over-twists in final RT-QuIC fibrils seeded with
samples of PD (n = 5) and samples of MSA (n = 5). As shown, the
distance between over-twists in α-synuclein fibrils obtained from RT-
QuIC products seeded with OM of MSA patients (orange arrows)
was about 142 ± 1.3 nm (mean ± standard error of the mean) while
that of PD patients (green arrows) was shorter and about 131 ± 1.1
nm and such differences were statistically significant (p < 0.0001,
Mann-Withney U test). Scale bar: 35 nm. b TEM images of the same
samples taken at higher magnification. Scale bar: 23 nm
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factors able to cross-seed rec-αS. PD and MSA samples
were characterized by higher rec-αS seeding efficiency
compared to PSP and CBD. In particular, almost all
MSA samples (9/11) and more than half of PD samples
(10/18) were able to induce rec-αS aggregation. Prob-
ably, the presence of abnormally folded α-synuclein in
these samples was more efficient in stimulating rec-αS
aggregation (homologous seeding). At difference, CBD
and PSP samples did not induce aggregation of rec-αS,
except for 2 out of 12 PSP and 1 out of 6 CBD. These
results might have several explanations and here we re-
port some of our hypotheses. First of all, since these
pathologies are clinically diagnosed using criteria whose
accuracy is not absolute, it might be that the clinical
diagnosis was not correct. Other options to be consid-
ered include the fact that, as previously described, some
of these diseases might share an incidental Lewy body
deposition or that such phenomenon may be neither
incidental nor coincidental, thus α-synuclein represents
the unique pathological protein of otherwise usually tau-
related clinical phenotypes [24]. Alternatively, some
strains of tau might be more effective than others in
cross-seed rec-αS aggregation, and the efficiency of such
phenomenon may be amount-dependent [73–76]. Fur-
thermore, OM is continuously regenerating and the
amount of abnormally folded tau could depend on this
process [77]. Unfortunately, collection and use of OM
samples in the diagnostic field of neurodegenerative dis-
eases is being born in the most recent years and it is not
possible to perform retrospective analysis or compare
data with neuropathological results to verify the sensitiv-
ity of the technique. For this reason, considered the lim-
ited number of samples analyzed, we decided not to
calculate both sensitivity and specificity of the assay.
Indeed, in contrast to prion diseases which have much
shorter duration compared to PD and MSA, the autopsy
confirmation might take many years. Therefore, we are
aimed at collecting data and following up our patients
for gathering information to be compared with neuro-
pathological results in the future.
Notably, considering the accuracy of the in vivo diag-
nosis, a percentage of the patients of our case series
might have been clinically misdiagnosed. Furthermore,
regeneration of OM might influence the total amount of
pathological α-synuclein present in the samples, thus
decreasing RT-QuIC sensitivity. Recent evidence demon-
strated an important drainage of CSF through the olfac-
tory mucosa [78]. For this reason, our RT-QuIC results
might have been influenced by a combination of both
OM and CSF and their relative content of abnormally
folded proteins. Another important point is that PD is
characterized by a remarkable phenotypic heterogeneity
that might be associated with different abnormal
conformers of α-synuclein [15, 79–81]. Such strains
might possess different seeding properties for rec-αS,
thus explaining why some PD samples were not detected
in our assay, in relation to the low sample size of the
subjects evaluated. Moreover, the concomitant presence
of other misfolded proteins (e.g. Aβ or tau) in OM sam-
ples might have influenced the aggregation properties of
rec-αS.
Recent data from the literature have demonstrated that
RT-QuIC might efficiently discriminate between Parkinson’s
disease and other parkinsonisms [82, 83]. In some cases, the
same RT-QuIC substrate can acquire distinct abnormal
structures if supplemented with different seeds. Hence, we
decided to verify whether OM of PD and MSA patients
were able to induce the formation of α-synuclein aggregates
characterized by disease-related biochemical and morpho-
logical features. Results of these analyses demonstrated that
rec-αS acquired peculiar features when seeded with PD or
MSA samples. In particular, α-synuclein fibrils produced by
MSA showed three PK-resistant bands migrating at around
6–8, and 22 kDa and TEM analysis showed that these fibrils
were characterized by the presence of over-twists whose dis-
tance was about 141 ± 1.3 nm (mean ± standard error of the
mean). In contrast, α-synuclein fibrils produced by PD
samples were significantly less resistant to PK digestion (p =
0.0061, Mann-Withney U test) and possessed one faint band
migrating at around 6–8 kDa with distances between over
-twists of about 131 nm±1.1 nm. These structural differ-
ences were statistically significant (p < 0.0001, Mann-With-
ney U test) and contribute in demonstrating that PD and
MSA are caused by different strains of α-synuclein [70] that
could effectively transmit their specific conformations to the
same substrate. Moreover, differences in post-translational
modifications of α-synuclein (e.g. phosphorylation) or in the
size of the oligomeric α-synuclein seeds in PD and MSA
might have influenced the RT-QuIC kinetics and the abnor-
mal structures acquired by the substrate. Previous RT-QuIC
experiments successfully demonstrated the presence of
pathological α-synuclein in CSF samples collected from pa-
tients with PD and DLB, but none of them reported the pos-
sibility to recognize disease-specific abnormal protein
conformers [43–46, 72].
The fact that our samples were collected from patients
without neuropathological confirmation represents a rele-
vant but at present not addressable limitation of our study.
Vascular leukoencephalopathy was observed in 4 patients,
who all received a clinical diagnosis of Parkinson’s disease
according to Postuma criteria [18]. However, these
patients, having evidence of only mild vascular disease
and in cerebral regions unlikely associated with motor
symptoms, did not meet criteria for vascular parkinsonism
[84, 85] and were not excluded from the analysis. It is
worth noting, however, that removal of these patients
from analysis resulted in detection of α-synuclein seeding
activity in 10 out of 14 OM samples, thus reaching an
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accuracy which is comparable to that of the RT-QuIC
analysis of CSF [43, 44]. Such observations might be better
defined in the future by using OM samples collected from
patients neuropathologically verified.
Conclusions
Our study provides the proof-of-concept that olfactory
mucosa samples collected from patients with PD and
MSA possess seeding activities for α-synuclein. These re-
sults represent a starting point for future studies aimed at
[1] estimating sensitivity and specificity of RT-QuIC ana-
lysis on OM samples useful for PD and MSA diagnosis,
[2] comparing the sensitivity of OM analysis with that of
CSF simultaneously collected from the same patient, [3]
integrating RT-QuIC analysis of CSF and OM with other
instrumental and biochemical data and verifying whether
this can significantly improve the clinical diagnostic accur-
acy of PD and other neurodegenerative parkinsonisms.
Thus, if these observations will be confirmed and ex-
tended, α-synuclein RT-QuIC integrated with biochemical
and TEM analyses may turn out to be a biomarker for the
preclinical diagnosis of MSA and PD. Finally, RT-QuIC
might offer a great opportunity to test the efficiency of
several compounds to interfere with the process of rec-αS
aggregation triggered by distinct α-synuclein strains, thus
laying the foundations for a precision medicine.
Additional files
Additional file 1: Table S1. Detailed clinical information of each patient
and related RT-QuIC results of OM analyses. (XLSX 16 kb)
Additional file 2: Figure S1. Biochemical analyses of RT-QuIC products. a
Western blot analyses of RT-QuIC aggregates seeded with 10− 3 dilutions of
BH of PD, MSA and FTDP-17 subjects. Samples show the same banding
profile. Blots were immunostained with the AS08 358 antibody. Numbers in
the right indicate the position of molecular weights. b Western blot
analyses of RT-QuIC aggregates seeded with OM samples of patients with
tauopathies. Samples show a banding profile comparable to that of MSA
seeded RT-QuIC reactions. Blots were immunostained with the AS08 358
antibody. Numbers in the right indicate the position of molecular weights. c
Epitope mapping of RT-QuIC aggregates seeded with OM samples of
patients with PD and MSA. C-terminal (4D6 and AB5038) antibodies did not
detect any typical PK-resistant α-synuclein band associated with PD or MSA,
while the NAC antibody (5C2) detected a faint PK resistant α-synuclein,
especially in MSA seeded samples. Numbers in the right indicate the
position of molecular weights. Dashed lines in a, b and c indicate
cropped images from separate gels. (PDF 93 kb)
Additional file 3: Figure S2. (.pdf) TEM images of RT-QuIC products
seeded with OM samples derived from CBD and PSP patients.
Measurements of the distance between over-twists in final RT-QuIC
products seeded with CBD (n = 1) and PSP (n = 1) samples and
comparison with those obtained from PD and MSA patients. As shown,
the distance between over-twists in α-synuclein fibrils obtained from
RT-QuIC products seeded with OM of CBD (black arrows) and PSP (brown
arrows) patients was about 115 ± 1.7 nm (mean ± standard error of the
mean) and 155 ± 1.5 nm, respectively. Scale bar: 35 nm. (PDF 30 kb)
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